Contact us

Please use the form below to get in touch with us, or email us directly by clicking here. ∎

Disclaimer

Our content is presented for informational purposes only, and should not be construed as investment, legal, medical or health advice.

Psychedelic Funding Update: Q2 2025July 9, 2025
Q1 2025 saw around $152M flow into psychedelics companies, with Lykos Therapeutics' $50M Series B round representing one of the first major private financings in quite some time. Explore key trends, public vs. private dynamics, and how the markets are reacting to trial and regulatory news in our Q1 roundup.
From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy PlaybookJuly 7, 2025
In a candid conversation with Psychedelic Alpha’s Josh Hardman, former U.S. Senator Kyrsten Sinema shares her case for ibogaine, sidesteps what she describes as ‘drama’, and lays out a strategy for funding research into the atypical psychedelic. Framing FDA approval as the north star, Sinema positions ibogaine as a transformative treatment option for conditions ranging from PTSD through to traumatic brain injury and Parkinson’s.
Oregon Psilocybin Services Tracker: Q1 2025July 4, 2025
As the first cut of data from Oregon's psilocybin program becomes available, we take a deep dive into emerging trends through various data visualisations and analysis. This marks the first instalment of our new Oregon Psilocybin Services Tracker, which will produce analysis of each cut of data as it is released. ∎
Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of PsychedelicsJuly 3, 2025
Psychedelic Alpha’s Charles Bliss speaks with Chris Timmermann, Research Fellow in Neuroscience, Meditation and Psychedelics at University College London, about why understanding and integrating psychedelic experiences may be just as vital for personal growth as for treating mental illness.
Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing ModelJuly 1, 2025
We cover Beckley Psytech and atai Life Sciences' conference call this morning, where company executives provided further details on the Phase 2b readout of intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression and took aim at their closest competitor's model.

Contact us

Disclaimer

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights